 Shares of Nkarta Inc. NKTX, -2.51 soared 42.7 in premarket trading on Monday after the company reported positive Phase 1 clinical data for two experimental CAR-T therapies. Three of five patients with pre-treated acute myeloid leukemia reported a complete response after undergoing treatment with one of the investigational therapies. 